Chinook Therapeutics, Inc. (KDNY) Financial Statements (2024 and earlier)

Company Profile

Business Address 400 FAIRVIEW AVENUE NORTH, SUITE 900
SEATTLE, WA 98109
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments350,376378,325373,283362,614276,099286,837
Cash and cash equivalents118,495115,438126,072145,927103,500181,724
Short-term investments231,881262,887247,211216,687172,599105,113
Receivables2,4441,0912,9193,1152,94710,061
Other undisclosed current assets5,8246,1765,4685,6706,7273,741
Total current assets:358,644385,592381,670371,399285,773300,639
Noncurrent Assets
Operating lease, right-of-use asset47,34548,97050,54652,27753,92255,385
Property, plant and equipment16,97416,90816,82717,50018,26318,935
Long-term investments and receivables9,65511,06029,53047,93261,13476,420
Long-term investments9,65511,06029,53047,93261,13476,420
Intangible assets, net (including goodwill)60,52160,95461,38761,81862,24762,676
Goodwill117117117117117117
Intangible assets, net (excluding goodwill)60,40460,83761,27061,70162,13062,559
Restricted cash and investments2,0742,0742,0742,0742,0742,074
Other noncurrent assets7,4627,3267,1027,0426,6576,474
Other undisclosed noncurrent assets41,20041,20041,20041,20041,20041,200
Total noncurrent assets:185,231188,492208,666229,843245,497263,164
TOTAL ASSETS:543,875574,084590,336601,242531,270563,803
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities15,91220,85727,48514,62612,54715,375
Employee-related liabilities7,8114,8443,4786,455
Accounts payable9,7749,75111,8434,9079,0398,580
Accrued liabilities6,13811,1067,8314,87530340
Other undisclosed current liabilities35,05229,97817,25114,85524,01924,710
Total current liabilities:50,96450,83544,73629,48136,56640,085
Noncurrent Liabilities
Long-term debt and lease obligation:   35,75937,16638,46139,589
Liabilities, other than long-term debt42,72443,9904,7754,9555,4855,895
Deferred income tax liabilities5,0765,076735735735735
Operating lease, liability33,17834,49435,75937,16638,46139,589
Business combination, contingent consideration, liability4,4704,4204,0404,2204,7505,160
Other undisclosed noncurrent liabilities37,79437,31830,43022,50923,96324,591
Total noncurrent liabilities:80,51881,30870,96464,63067,90970,075
Total liabilities:131,482132,143115,70094,111104,475110,160
Equity
Equity, attributable to parent412,393441,941474,636507,131426,795453,643
Common stock776665
Additional paid in capital893,905864,729835,330810,754691,776685,459
Accumulated other comprehensive loss(1,711)(3,164)(3,623)(2,531)(1,537)(55)
Accumulated deficit(479,808)(419,631)(357,077)(301,098)(263,450)(231,766)
Total equity:412,393441,941474,636507,131426,795453,643
TOTAL LIABILITIES AND EQUITY:543,875574,084590,336601,242531,270563,803

Income Statement (P&L) ($ in thousands)

6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
Revenues1,8285122,5014182,69751,236
Gross profit:1,8285122,5014182,69751,236
Operating expenses(62,287)(52,717)(52,007)(38,658)(34,120)(31,406)
Other undisclosed operating income (loss)(959)(7,701)(8,172)1,555609(7,441)
Operating income (loss):(61,418)(59,906)(57,678)(36,685)(30,814)12,389
Nonoperating income (expense)3,1022,4471,690767(95)5
Investment income, nonoperating3,102     
Other nonoperating income (expense)   1,690767(95)5
Income (loss) from continuing operations before equity method investments, income taxes:(58,316)(57,459)(55,988)(35,918)(30,909)12,394
Income (loss) from equity method investments(1,861)(754)9(1,730)(775)(1,552)
Income (loss) from continuing operations before income taxes:(60,177)(58,213)(55,979)(37,648)(31,684)10,842
Income tax expense      (3,297)
Other undisclosed loss from continuing operations  (4,341)    
Income (loss) from continuing operations:(60,177)(62,554)(55,979)(37,648)(31,684)7,545
Income (loss) before gain (loss) on sale of properties:(55,979)(37,648)(31,684)7,545
Net income (loss) available to common stockholders, diluted:(60,177)(62,554)(55,979)(37,648)(31,684)7,545

Comprehensive Income ($ in thousands)

6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
12/31/2021
Q4
Net income (loss):(60,177)(62,554)(55,979)(37,648)(31,684)7,545
Other comprehensive income (loss)1,453 (1,092)(994)(1,482) 
Other undisclosed comprehensive loss  (3,109)   (66)
Comprehensive income (loss):(58,724)(65,663)(57,071)(38,642)(33,166)7,479
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 3,568   (362)
Comprehensive income (loss), net of tax, attributable to parent:(58,724)(62,095)(57,071)(38,642)(33,166)7,117

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: